NCT02603887 2026-01-29
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
M.D. Anderson Cancer Center
Rutgers, The State University of New Jersey
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins